Barré Tangui, Cazorla Géraldine, Di Beo Vincent, Lopez Fabienne, Radoszycki Lise, Maradan Gwenaëlle, Baunez Christelle, Carrieri Patrizia
Aix-Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.
Principes Actifs, Lieusaint, France.
Clin Park Relat Disord. 2024 Nov 20;11:100286. doi: 10.1016/j.prdoa.2024.100286. eCollection 2024.
Cannabis and cannabidiol (CBD) may potentially alleviate symptoms and improve the quality of life of people with Parkinson's disease (PD), although clinical results to date have provided conflicting evidence. In France, cannabis use is illegal outside the current restricted medical cannabis experimental framework which does not include PD as an eligible condition. In contrast, CBD products are legal and are easily available. We aimed to evaluate the acceptability of therapeutic cannabis and CBD use, and to assess cannabinoid-related attitudes among people with PD in France, with a view to assessing the potential inclusion of medical cannabinoids in PD treatment options.
We conducted a French nationwide online survey among people with PD. Cannabis and CBD acceptability levels were derived from the answers to four questions. Logistic regressions were performed to identify factors associated with these levels. We also collected data on knowledge, information-seeking, and barriers to self-medication.
Of 1136 participants, acceptability levels of medical cannabis and CBD use were 81.7% and 87.4%, respectively. For both substances, acceptability was associated with the presence of anxiety symptoms, greater knowledge about cannabinoids, seeking information on medical cannabis, and considering the risk of cannabis dependence to be low. A fear of dependence was one of the main barriers to using either substance; healthcare providers were rarely mentioned as sources of information on medical cannabis.
Acceptability levels of cannabis and CBD were high. Acceptability was associated with knowledge and perceptions of cannabinoids. Given ongoing misconceptions about the effects and risks associated with CBD, disseminating accurate information could increase its acceptability in people with PD.
大麻和大麻二酚（CBD）可能会缓解帕金森病（PD）患者的症状并改善其生活质量，尽管迄今为止的临床结果提供了相互矛盾的证据。在法国，除了当前有限的医用大麻实验框架（该框架不包括将PD作为适用病症）之外，使用大麻是非法的。相比之下，CBD产品是合法的且很容易获得。我们旨在评估治疗性使用大麻和CBD的可接受性，并评估法国PD患者对大麻素的态度，以便评估医用大麻素纳入PD治疗方案的可能性。
我们在法国全国范围内对PD患者进行了一项在线调查。大麻和CBD的可接受性水平来自对四个问题的回答。进行逻辑回归以确定与这些水平相关的因素。我们还收集了有关知识、信息寻求和自我用药障碍的数据。
在1136名参与者中，医用大麻和CBD使用的可接受性水平分别为81.7%和87.4%。对于这两种物质，可接受性都与焦虑症状的存在、对大麻素的更多了解、寻求医用大麻信息以及认为大麻依赖风险较低有关。对依赖的恐惧是使用这两种物质的主要障碍之一；很少有人提及医疗保健提供者是医用大麻信息的来源。
大麻和CBD的可接受性水平较高。可接受性与对大麻素的了解和认知有关。鉴于对CBD的影响和风险仍存在误解，传播准确信息可能会提高其在PD患者中的可接受性。
